Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...
After a pleasant week of spring-like temperatures in the area, a pattern shift will bring a warm front and a strong cold front through the area this weekend. Not only is the cold front going to ...
British workers are heading back to the office in greater numbers, but their commuting habits are changing in unexpected ways. According to the latest Movers Index from Virgin Media O2 Business, 88% ...
Despite California banning the sale of puppies from retail stores that were commonly purchased from puppy mills in 2017, an L.A. Times investigation found that puppy mill brokers transport dogs in ...
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
Declines in Chinese crude imports and demand filled by illicit barrels from Iran and Russia helped hold down VLCC rates through much of the second half of last year — a story that only unwound ...
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback